Heart transplant survivor fights to keep access to anti-rejection drug
Why This Matters
Key context: At 11, Payton Herres received a donated heart after years of health problems caused by Ebstein’s anomaly. Fifteen years later, she faced a fight to access everolimus, the anti-rejection medicine she had relied on since 2013. After her insurer stopped covering the drug and its cost rose sharply, Herres turned to social media. Her story went viral and reached Mark Cuban, whose pharmacy began supplying the medicine at a lower cost. This development from timesofindia.indiatimes.com highlights ongoing changes in the sector.
At 11, Payton Herres received a donated heart after years of health problems caused by Ebstein’s anomaly. Fifteen years later, she faced a fight to access everolimus, the anti-rejection medicine she had relied on since 2013. After her insurer stopped covering the drug and its cost rose sharply, Herres turned to social media. Her story went viral and reached Mark Cuban, whose pharmacy began supplying the medicine at a lower cost.
Curation & Context
This page summarizes a public news report from timesofindia.indiatimes.com. Global News Hub provides the "Why This Matters" takeaway using editorial insights and AI curation to give readers rapid, high-value context before they click through to read the full article.